J. David Jentsch

Last updated

J. David Jentsch
Photo of J. David Jentsch.jpg
Jentsch in 2020.
Born (1972-04-09) April 9, 1972 (age 52)
Alma mater Johns Hopkins University
Yale University
Awards AAAS Award for Scientific Freedom and Responsibility
Scientific career
Institutions Binghamton University
University of California, Los Angeles
Thesis Neurochemical substrates of cognitive dysfunction produced by the psychotomimetic drug phencyclidine  (1999)
Doctoral advisor Robert H. Roth [1]
Website Jentsch Laboratory

James David Jentsch (born April 9, 1972) is an American neuroscientist. He is a SUNY Distinguished Professor and Chair of the Department of Psychology at Binghamton University. His research considers the neurobiological origins of psychoses and addiction. Jentsch was awarded the 2011 AAAS Award for Scientific Freedom and Responsibility.

Contents

Early life and education

Jentsch was born on April 9, 1972, in Seguin, Texas. [2] He studied behavioural biology at Johns Hopkins University. He moved to Yale University for his graduate studies, where he specialised in neurobiology. [3] Here he worked on the biochemical changes associated with the abuse of psychotomimetic and stimulant drugs. [1] He completed his doctoral research under the supervision of Robert Henry Roth. Jentsch was a postdoctoral scholar at the University of Pittsburgh, where he worked in the department of neuroscience. [3]

Research and career

Jentsch joined the University of California, Los Angeles in 2001. [3] He was promoted to Associate Professor in 2007, and Associate Director of the Brain Research Institute and Professor in 2009. In 2009 Jentsch woke up to find that his car had been firebombed by animal rights activists. [4] The firebombing was one of a series of attacks against UCLA researchers, criticising Jentsch's use of animals in his research on schizophrenia. [4] [5] The following summer Jentsch was on the receiving end of several violent threats from Camille Marino, who told Jentsch that the thought of his death amused her "immensely". [6] Jentsch founded UCLA Pro-Test, a group that looked to take on the alleged misinformation shared by animal rights activists and tackle violent extremism. [7] [8]

Jentsch was made Empire Innovation Professor of Psychology at Binghamton University in 2015. His research looks to establish the neural and genetic mechanisms that underpin alcohol and drug addiction. [9]

At Binghamton Jentsch was awarded a $11,700,000 grant from the National Institute on Drug Abuse to investigate cocaine addiction, and the neural pathways that can result in someone becoming addicted. [10] Jentsch is interested in identifying the genes that can predispose people to drug addiction, as this may be able to inform life-saving interventions. [10] [11]

Jentsch serves on the advisory board of the Lifeboat Foundation. [1]

Awards and honours

Selected publications

Personal life

Jentsch is openly gay and is part of the organisation 500 Queer Scientists. [16] He uses social media including Twitter to share his research and experiences as a scientist. [17]

Related Research Articles

<span class="mw-page-title-main">Phencyclidine</span> Dissociative hallucinogenic drug, mostly used recreationally

Phencyclidine or phenylcyclohexyl piperidine (PCP), also known in its use as a street drug as angel dust among other names, is a dissociative anesthetic mainly used recreationally for its significant mind-altering effects. PCP may cause hallucinations, distorted perceptions of sounds, and violent behavior. As a recreational drug, it is typically smoked, but may be taken by mouth, snorted, or injected. It may also be mixed with cannabis or tobacco.

Neuropsychopharmacology, an interdisciplinary science related to psychopharmacology and fundamental neuroscience, is the study of the neural mechanisms that drugs act upon to influence behavior. It entails research of mechanisms of neuropathology, pharmacodynamics, psychiatric illness, and states of consciousness. These studies are instigated at the detailed level involving neurotransmission/receptor activity, bio-chemical processes, and neural circuitry. Neuropsychopharmacology supersedes psychopharmacology in the areas of "how" and "why", and additionally addresses other issues of brain function. Accordingly, the clinical aspect of the field includes psychiatric (psychoactive) as well as neurologic (non-psychoactive) pharmacology-based treatments. Developments in neuropsychopharmacology may directly impact the studies of anxiety disorders, affective disorders, psychotic disorders, degenerative disorders, eating behavior, and sleep behavior.

<span class="mw-page-title-main">Latent learning</span> Subconscious retention of information without reinforcement

Latent learning is the subconscious retention of information without reinforcement or motivation. In latent learning, one changes behavior only when there is sufficient motivation later than when they subconsciously retained the information.

Kent C. Berridge is an American academic, currently working as a professor of psychology (biopsychology) and neuroscience at the University of Michigan. Berridge was a joint winner of the 2018 Grawemeyer Award for Psychology.

<span class="mw-page-title-main">George Aghajanian</span> Pioneer in neuropharmacology (1932–2023)

George K. Aghajanian was an American psychiatrist who was Emeritus Foundations Fund Professor at the Yale School of Medicine, New Haven, Connecticut, in the Department of Psychiatry. He was a pioneer in the area of neuropharmacology. He also served as a member of the NARSAD Scientific Advisory Board.

Cocaine dependence is a neurological disorder that is characterized by withdrawal symptoms upon cessation from cocaine use. It also often coincides with cocaine addiction which is a biopsychosocial disorder characterized by persistent use of cocaine and/or crack despite substantial harm and adverse consequences. The Diagnostic and Statistical Manual of Mental Disorders, classifies problematic cocaine use as a stimulant use disorder. The International Classification of Diseases, includes "Cocaine dependence" as a classification (diagnosis) under "Disorders due to use of cocaine".

<span class="mw-page-title-main">Eglumetad</span> Chemical compound

Eglumetad is a research drug developed by Eli Lilly and Company, which is being investigated for its potential in the treatment of anxiety and drug addiction. It is a glutamate derived compound and its mode of action implies a novel mechanism.

<span class="mw-page-title-main">Sonepiprazole</span> Chemical compound

Sonepiprazole (U-101,387, PNU-101,387-G) is a drug of the phenylpiperazine class which acts as a highly selective D4 receptor antagonist. In animals, unlike D2 receptor antagonists like haloperidol, sonepiprazole does not block the behavioral effects of amphetamine or apomorphine, does not alter spontaneous locomotor activity on its own, and lacks extrapyramidal and neuroendocrine effects. However, it does reverse the prepulse inhibition deficits induced by apomorphine, and has also been shown to enhance cortical activity and inhibit stress-induced cognitive impairment. As a result, it was investigated as an antipsychotic for the treatment of schizophrenia in a placebo-controlled clinical trial, but in contrast to its comparator olanzapine no benefits were found and it was not researched further for this indication.

<span class="mw-page-title-main">PD-168,077</span> Chemical compound

PD-168,077 is a drug which acts as a dopamine agonist selective for the D4 subtype, which is used for researching the role of D4 receptors in the brain, particularly relating to learning and memory. It also induces penile erections in rats.

<span class="mw-page-title-main">SB-206553</span> Chemical compound

SB-206553 is a drug which acts as a mixed antagonist for the 5-HT2B and 5-HT2C serotonin receptors. It has anxiolytic properties in animal studies and interacts with a range of other drugs. It has also been shown to act as a positive allosteric modulator of α7 nicotinic acetylcholine receptors. Modified derivatives of SB-206553 have been used to probe the structure of the 5-HT2B receptor.

Michael J. Kuhar, is an American neuroscientist, author, and Candler Professor of Neuropharmacology at The Emory National Primate Research Center of Emory University. He is a Georgia Research Alliance eminent scholar, and a senior fellow in the Center for Ethics at Emory. He was previously a professor at Johns Hopkins University School of Medicine and branchchief at the National Institute on Drug Abuse.

<span class="mw-page-title-main">Carl Hart</span> American neuroscientist (born 1966)

Carl L. Hart is an American psychologist and neuroscientist, working as the Mamie Phipps Clark Professor of Psychology at Columbia University. Hart is known for his research on drug abuse and drug addiction, his advocacy for the legalization of recreational drugs, and his recreational use of drugs. Hart became the first tenured African-American professor of sciences at Columbia University. He is the author of two books for the general public, High Price: A Neuroscientist's Journey of Self-Discovery that Challenges Everything You Know about Drugs and Society (2013) and Drug Use for Grown-Ups: Chasing Liberty in the Land of Fear (2021).

<span class="mw-page-title-main">Patricia Janak</span> American neuroscientist (born 1965)

Patricia Janak is a Bloomberg Distinguished Professor at Johns Hopkins University who studies the biological basis of behavior through associative learning. Janak applies this research to pathological behaviors, such as addiction and posttraumatic stress disorder, to improve understanding of how stimuli affect relapse and responses.

Hyperlocomotion, also known as locomotor hyperactivity, hyperactivity, or increased locomotor activity, is an effect of certain drugs in animals in which locomotor activity is increased. It is induced by certain drugs like psychostimulants and NMDA receptor antagonists and is reversed by certain other drugs like antipsychotics and certain antidepressants.

Marian Rita Weinbaum Fischman was an American psychologist who researched narcotics and addiction.

<span class="mw-page-title-main">Kate Wassum</span> American neuroscientist

Kate Wassum is an American neuroscientist and professor of behavioral neuroscience at the University of California, Los Angeles. Wassum probes the neural circuits underlying appetitive associative learning the circuit dynamics that give rise to diverse motivated behaviors.

<span class="mw-page-title-main">Bita Moghaddam</span> Iranian-American neuroscientist

Bita Moghaddam is an Iranian-American neuroscientist and author. She is currently the Ruth Matarazzo Professor of Behavioral Neuroscience at Oregon Health & Science University. Moghaddam investigates the neuronal processes underlying emotion and cognition as a first step to designing strategies to treat and prevent brain illnesses.

Catharine Antonia Winstanley is a Canadian behavioural neuroscientist. She is a Full professor in the Department of Psychology and the Djavad Mowafaghian Centre for Brain Health at the University of British Columbia. In this role, she co-created the world’s first rat casino in an animal lab experiment to model human gambling. In 2020, Winstanley was elected to the Royal Society of Canada's College of New Scholars, Artists and Scientists.

Marina Elizabeth Wolf is an American neuroscientist and Professor of Behavioral Neuroscience at Oregon Health & Science University. Previously she served as Professor and Chair of the Department of Neuroscience in the Chicago Medical School at Rosalind Franklin University of Medicine and Science. She has been a pioneer in studying the role of neuronal plasticity in drug addiction. Her laboratory is particularly interested in understanding why individuals recovering from substance use disorder remain vulnerable to drug craving and relapse even after long periods of abstinence.

Terry Earl Robinson is a biopsychologist and neuroscientist, and the Elliot S. Valenstein Distinguished University Professor of Psychology & Neuroscience at The University of Michigan.

References

  1. 1 2 3 "Lifeboat Foundation Bios: Professor J. David Jentsch". Lifeboat Foundation . Retrieved February 29, 2020.
  2. 1 2 "J. David Jentsch, Curriculum vitae"" (PDF). Binghamton University. Retrieved May 2, 2020.
  3. 1 2 3 "James Jentsch, Ph.D." Semel Institute for Neuroscience & Human Behavior. Retrieved February 29, 2020.
  4. 1 2 "A Target of Violence". UCLA Magazine. Retrieved February 29, 2020.
  5. "UCLA professor stands up to violent animal rights activists". Los Angeles Times. April 13, 2009. Retrieved February 29, 2020.
  6. "Three Who Stood Up - U Magazine - UCLA Health - Los Angeles, CA". www.uclahealth.org. Retrieved February 29, 2020.
  7. "Pro-Test for Science". Speaking of Research. March 28, 2009. Retrieved February 29, 2020.
  8. "Defending animal research". APA. Retrieved February 29, 2020.
  9. "How to Engage Institutions to Publicly Support Animal Research". neuronline.sfn.org. Retrieved February 29, 2020.
  10. 1 2 "BU psychology professor receives $11.7M grant for research on drug addiction - Pipe Dream". www.bupipedream.com. August 30, 2016. Retrieved February 29, 2020.
  11. "New NIH-funded study to identify risks for vulnerability to drug addiction". Scienmag: Latest Science and Health News. August 23, 2016. Retrieved February 29, 2020.
  12. 1 2 "Psychology Department Faculty Awards | UCLA Psychology Department". www.psych.ucla.edu. Retrieved March 1, 2020.
  13. Abuse, National Institute on Drug (February 6, 2020). "Society for Neuroscience Jacob P. Waletzky Memorial Award". www.drugabuse.gov. Retrieved February 29, 2020.
  14. "2011 Award for Scientific Freedom and Responsibility Recipient". American Association for the Advancement of Science. Retrieved February 29, 2020.
  15. "Jentsch, Ringach honored for biomedical research leadership". UCLA. Retrieved February 29, 2020.
  16. "J. David Jentsch". 500 Queer Scientists. Retrieved May 2, 2020.
  17. "Jentsch Lab at Binghamton University". August 16, 2018. Retrieved May 2, 2020.[ permanent dead link ]